STAT+: PepGen says early trial for muscular dystrophy drug looks promising

🇺🇸 STAT News Health (US) —
STAT+: PepGen says early trial for muscular dystrophy drug looks promising

AI Summary

PepGen reports promising early trial results for a candidate treatment for myotonic dystrophy type 1. The company says the drug is correcting more of the genetic abnormality associated with the disease.

PepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.

Health PepGen myotonic dystrophy type 1 drug candidate clinical trial genetic disease

Read original source →